

Development of Sustainable Bioprocesses Modeling and Assessment

ELMAR HEINZLE

University Saarland, Saarbrücken, Germany

ARNO P. BIWER

University Saarland, Saarbrücken, Germany

CHARLES L. COONEY

Massachusetts Institute of Technology, Cambridge, MA, USA



John Wiley & Sons, Ltd

Development of Sustainable Bioprocesses

Development of Sustainable Bioprocesses Modeling and Assessment

ELMAR HEINZLE

University Saarland, Saarbrücken, Germany

ARNO P. BIWER

University Saarland, Saarbrücken, Germany

CHARLES L. COONEY

Massachusetts Institute of Technology, Cambridge, MA, USA



John Wiley & Sons, Ltd

Copyright © 2006 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester,
West Sussex PO19 8SQ, England
Telephone (+44) 1243 779777

Email (for orders and customer service enquiries): cs-books@wiley.co.uk
Visit our Home Page on www.wileyeurope.com or www.wiley.com

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher. Requests to the Publisher should be addressed to the Permissions Department, John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England, or emailed to permreq@wiley.co.uk, or faxed to (+44) 1243 770620.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The Publisher is not associated with any product or vendor mentioned in this book.

This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the Publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

Other Wiley Editorial Offices

John Wiley & Sons Inc., 111 River Street, Hoboken, NJ 07030, USA

Jossey-Bass, 989 Market Street, San Francisco, CA 94103-1741, USA

Wiley-VCH Verlag GmbH, Boschstr. 12, D-69469 Weinheim, Germany

John Wiley & Sons Australia Ltd, 42 McDougall Street, Milton, Queensland 4064, Australia

John Wiley & Sons (Asia) Pte Ltd, 2 Clementi Loop #02-01, Jin Xing Distripark, Singapore 129809

John Wiley & Sons Canada Ltd, 6045 Freemont Blvd, Mississauga, Ontario, L5R 4J3, Canada

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Library of Congress Cataloging-in-Publication Data

Heinzle, Elmar.

Development of sustainable bioprocesses : modeling and assessment / Elmar Heinzle, Arno P. Biwer, Charles L. Cooney.
p. cm.

Includes bibliographical references.

ISBN-13: 978-0-470-01559-9 (cloth : alk. paper)

ISBN-10: 0-470-01559-4 (cloth : alk. paper)

1. Biochemical engineering--Economic aspects. 2. Biochemical engineering--Environmental aspects. 3. Biochemical engineering--Computer simulation. I. Biwer, Arno P. II. Cooney, Charles L., 1944-- III. Title.
TP248.3.H45 2007
660.6'3--dc22

2006019153

British Library Cataloguing in Publication Data

A catalogue record for this book is available from the British Library

ISBN-10 0-470-01559-4

ISBN-13 978-0-470-01559-9

Typeset in 10/12pt Times by TechBooks, New Delhi, India.

Printed and bound in Great Britain by Antony Rowe, Chippenham, Wiltshire.

This book is printed on acid-free paper responsibly manufactured from sustainable forestry in which at least two trees are planted for each one used for paper production.

Dedicated To Our Families and Our Students

Contents

<i>Preface</i>	<i>Page</i>	xiii
<i>Acknowledgments</i>		xvii
<i>List of Contributors</i>		xix
PART I THEORETICAL INTRODUCTION		
1 Introduction		3
1.1 Bioprocesses		3
1.1.1 History of Biotechnology and Today's Situation		3
1.1.2 Future Perspectives		6
1.2 Modeling and Assessment in Process Development		7
2 Development of Bioprocesses		11
2.1 Types of Bioprocess and Bioproduct		11
2.1.1 Biocatalysts and Process Types		11
2.1.2 Raw Materials		17
2.1.3 Bioproducts		20
2.2 Bioreaction Stoichiometry, Thermodynamics, and Kinetics		23
2.2.1 Stoichiometry		23
2.2.2 Thermodynamics		28
2.2.3 Kinetics		29

2.3	Elements of Bioprocesses (Unit Operations and Unit Procedures)	32
2.3.1	Upstream Processing	33
2.3.2	Bioreactor	36
2.3.3	Downstream Processing	40
2.3.4	Waste Treatment, Reduction and Recycling	50
2.4	The Development Process	52
2.4.1	Introduction	52
2.4.2	Development Steps and Participants	53
3	Modeling and Simulation of Bioprocesses	61
3.1	Problem Structuring, Process Analysis, and Process Scheme	62
3.1.1	Model Boundaries and General Structure	62
3.1.2	Modeling Steps	63
3.2	Implementation and Simulation	66
3.2.1	Spreadsheet Model	66
3.2.2	Modeling using a Process Simulator	66
3.3	Uncertainty Analysis	71
3.3.1	Scenario Analysis	72
3.3.2	Sensitivity Analysis	73
3.3.3	Monte Carlo Simulation	75
4	Sustainability Assessment	81
4.1	Sustainability	81
4.2	Economic Assessment	82
4.2.1	Capital-Cost Estimation	83
4.2.2	Operating-Cost Estimation	88
4.2.3	Profitability Assessment	94
4.3	Environmental Assessment	95
4.3.1	Introduction	95
4.3.2	Structure of the Method	96
4.3.3	Impact Categories and Groups	99
4.3.4	Calculation of Environmental Factors	103
4.3.5	Calculation of Indices	105
4.3.6	Example Cleavage of Penicillin G	105
4.4	Assessing Social Aspects	107
4.4.1	Introduction	107
4.4.2	Indicators for Social Assessment	108
4.5	Interactions between the Different Sustainability Dimensions	112
PART II BIOPROCESS CASE STUDIES		
Introduction to Case Studies		121
5	Citric Acid – Alternative Process using Starch	125
5.1	Introduction	125
5.2	Fermentation Model	125

5.3	Process Model	128
5.4	Inventory Analysis	130
5.5	Environmental Assessment	132
5.6	Economic Assessment	134
5.7	Conclusions	135
6	Pyruvic Acid – Fermentation with Alternative Downstream Processes	137
6.1	Introduction	137
6.2	Fermentation Model	137
6.3	Process Model	138
6.3.1	Bioreaction and Upstream	138
6.3.2	Downstream Processing	141
6.4	Inventory Analysis	142
6.5	Environmental Assessment	144
6.6	Economic Assessment	145
6.7	Conclusions	145
7	L-Lysine – Coupling of Bioreaction and Process Model	155
	<i>Arnd Knoll, Jochen Buechs</i>	
7.1	Introduction	155
7.2	Basic Strategy	156
7.3	Bioreaction Model	156
7.4	Process Model	159
7.5	Coupling of Bioreaction and Process Model	162
7.5.1	Assumptions	163
7.6	Results and Discussion	164
8	Riboflavin – Vitamin B₂	169
	<i>Wilfried Storhas, Rolf Metz</i>	
8.1	Introduction	169
8.2	Biosynthesis and Fermentation	170
8.3	Production Process and Process Model	171
8.3.1	Upstream Processing	172
8.3.2	Fermentation	174
8.3.3	Downstream Processing	174
8.4	Inventory Analysis	174
8.5	Ecological Assessment	175
8.6	Economic Assessment	176
8.7	Discussion and Concluding Remarks	177
9	α-Cyclodextrin	181
9.1	Introduction	181
9.2	Reaction Model	182

9.3	Process Model	182
9.3.1	Solvent Process	182
9.3.2	Non-solvent Process	184
9.4	Inventory Analysis	185
9.5	Environmental Assessment	186
9.6	Economic Assessment	186
9.7	Conclusions	189
10	Penicillin V	193
10.1	Introduction	193
10.2	Modeling Base Case	193
10.2.1	Fermentation Model	193
10.2.2	Process Model	194
10.3	Inventory Analysis	196
10.4	Environmental Assessment	197
10.5	Economic Assessment	197
10.6	Monte Carlo Simulations	198
10.6.1	Objective Functions, Variables, and Probability Distributions	198
10.6.2	Results	201
10.7	Conclusions	206
11	Recombinant Human Serum Albumin	211
	<i>M. Abdul Kholiq, Elmar Heinzle</i>	
11.1	Introduction	211
11.2	Bioreaction Model	212
11.2.1	Stoichiometry	212
11.2.2	Multi-stage Fermentation and Feeding Plan	213
11.2.3	Total Broth Volume in Production Scale and Raw Material Consumption	214
11.3	Process Model	215
11.3.1	Bioreaction	215
11.3.2	Downstream Processing	215
11.4	Economic Assessment	218
11.5	Ecological Assessment	219
11.6	Conclusions	221
12	Recombinant Human Insulin	225
	<i>Demetri Petrides</i>	
12.1	Introduction	225
12.1.1	Two-chain Method	226
12.1.2	Proinsulin Method	226
12.2	Market Analysis and Design Basis	226
12.2.1	Process Description	227

12.2.2	Inventory Analysis and Environmental Assessment	233
12.2.3	Production Scheduling	234
12.3	Economic Assessment	235
12.4	Throughput-Increase Options	237
12.5	Conclusions	238
13	Monoclonal Antibodies	241
13.1	Introduction	241
13.2	Process Model	241
13.3	Inventory Analysis	243
13.4	Economic Assessment	245
13.5	Environmental Assessment	246
13.6	Uncertainty Analysis	247
13.6.1	Scenarios	247
13.6.2	Sensitivity Analysis	248
13.6.3	Monte Carlo Simulations	249
13.7	Conclusions	255
14	α-1-Antitrypsin from Transgenic Plant Cell Suspension Cultures	261
	<i>Elizabeth Zapalac, Karen McDonald</i>	
14.1	Introduction	261
14.2	Process Description	263
14.3	Model Description	263
14.4	Discussion	265
14.5	Conclusions	268
15	Plasmid DNA	271
	<i>Sindélia S. Freitas, José A. L. Santos, D. Miguel F. Prazeres</i>	
15.1	Introduction	271
15.1.1	General	271
15.1.2	Case Introduction	272
15.1.3	Process Description	272
15.2	Model Description	275
15.2.1	Bioreaction Section	275
15.2.2	Downstream Sections	276
15.3	Inventory Analysis	277
15.4	Economic Assessment	278
15.5	Environmental Assessment	281
15.6	Discussion	282
15.7	Conclusions	283
	Index	287

Preface

This book is intended to provide a framework for the development of sustainable bioprocesses. It includes methods for assessing both the economic and environmental aspects of biotechnological processes and illustrates their application in a series of case studies covering a broad range of products. Bioprocesses have accompanied human development from very early times. Currently, bioprocesses are gaining increased attention because of their enormous potential for the production of high-value products, especially in human health care and because of their inherent attribute as sustainable processes. New bio-industries have potential as efficient processes based on renewable resources characterized by minimal pollution. Modern methods of enzyme optimization and metabolic engineering are powerful tools for the development of novel efficient biocatalysts. The development of new bioprocesses is enhanced by the application of modern process modeling and simulation techniques, combined with assessment methods that are applied systematically in the very early phases of process development. Future sustainability essentially depends on the ability of industry to develop new processes which are (i) short- and long-term commercially successful, which (ii) at the same time are environmentally friendly using minimal resources that are preferably renewable and constitute a minimal environmental burden, and which (iii) generally satisfy the needs of society.

This book attempts to provide integrating frameworks in a manner useful to both the student in chemical and biochemical engineering, and the scientist and engineer engaged in process development. As time-to-market is a criterion of ever increasing importance, methods are needed which can deliver superior results in a short time. This is of central importance for professionals working in industries applying bioprocesses. Such professionals may be biochemical, chemical, and process engineers, but also biologists, chemists, environmental managers, and business economists. This book may also assist graduate and postgraduate students of economics, as well as environmental sciences. The intent is to

assist both students and professionals by providing a condensed introduction into the basic theory of bioprocess modeling and sustainability assessment methods, combined with typical case studies. The book is intended to supplement more comprehensive texts on process economics, biochemical reaction engineering, and bioseparation processes. The case studies are supplemented with fully operational models, which are all supplied on the accompanying CD. The models are built using the software SuperPro Designer,TM which is kindly supplied by Intelligen, Inc. (Scotch Plains, NJ, USA) in a version that allows running all examples. These case studies make the book particularly attractive to practitioners who would like to start modeling from an already well developed similar case to shorten development time. The only prerequisites required to be able to follow the book immediately is a basic understanding of bioprocesses and basic economic principles. The reader lacking this background is guided to literature filling these knowledge gaps.

We believe the book is unique in providing (i) an introduction to bioprocess modeling in combination with economic and environmental assessment methods, which both are important in a world with limited resources and increasing environmental pollution; (ii) the book cuts across multiple process industries, including pharmaceutical, biochemicals, chemicals, and food production. The methods presented are broadly applicable in all these fields; (iii) the book also addresses risk and uncertainty analysis, which are particularly important in early process and product development. These methods will help to efficiently direct research and development efforts, to reduce the risk of later stage failures, and to put decision-making on a fundamental basis; (iv) the unique set of case examples from various parts of biotechnology improves the understanding of this technology and provides a starting point for developing one's own specific model.

Organization of the Book

The book consists of two parts. The first part presents the essential, necessary theory, and part two consists of 11 case studies covering a broad range of bio-industries.

Chapter 1 starts with a short introduction to bioprocesses, outlining the expected future potential of biotechnological processing. This chapter also highlights the importance of modeling and simulation for developing sustainable bioprocesses.

Chapter 2, characterizing the development of bioprocesses, describes types of bioprocesses, raw materials, and bioproducts. Then, essentials of bioreaction stoichiometry, thermodynamics, and kinetics are introduced. The elements of bioprocesses described comprise those of upstream processing, bioreaction, downstream processing, utilities, and also waste treatment and recycling. This chapter is concluded by the description of the development process including managerial issues.

Chapter 3 provides a hands-on approach on setting up a process model and simulating it. This starts with problem structuring, process analysis, and setting up a process scheme. Then the implementation into a computer model is illustrated. This chapter concludes with methods of uncertainty analysis comprising scenario analysis, sensitivity analysis, and Monte Carlo simulations.

An integral part of the book is sustainability assessment, and a problem-oriented approach to process development is described in Chapter 4. The economic assessment follows standard procedures, as already included in SuperPro DesignerTM. The environmental

assessment, which is primarily based on mass and energy balances of the process, uses an ABC method developed for such types of problems. Social assessment and safety are briefly addressed but not incorporated in the case studies.

The second part describes 11 case studies which originate from our own work and from various persons around the world who used modeling tools for bioprocesses and who kindly accepted our invitation to contribute to this book. All process model examples are implemented into SuperPro DesignerTM. An attached CD-ROM contains the process models described in the book. The models are selected such that characteristic examples of each application area covered are comprized. These major areas of bioprocess industries covered include bulk biochemicals, fine chemicals, enzymes, and low- and high-molecular-weight pharmaceuticals. These elaborate examples are of inestimable value in providing a quick hands-on approach, which will be highly welcomed both by students and professionals already working in bioprocess industries.

The authors' different backgrounds help to cover the broad field. Prof. Charles L. Cooney from the Chemical Engineering Department at MIT in Cambridge, Massachusetts, USA has extended experience in chemical and biochemical engineering. He initiated the creation of SuperPro DesignerTM during the PhD work of Demetri Petrides, who is now chief executive of Intelligen, Inc. Throughout his career he closely cooperated with firms actively engaged in biochemical process development. Prof. Elmar Heinzle from the Biochemical Engineering Institute of the Saarland University, Germany studied Applied Chemistry at the Technical University of Graz, Austria and specialized in Biochemical Engineering. During his time at the Swiss Federal Institute of Technology (ETH), Zurich, Switzerland and at the Saarland University he also closely cooperated with various chemical and biochemical industries and was involved in process modeling and assessment. He was also engaged with modeling biochemical kinetics and reactors throughout his carrier and published two books with Drs I.J. Dunn, J. Ingham and J.E. Prenosil [Ingham, J., Dunn, I.J., Heinzle, E., Prenosil, J.E. (2000): *Chemical Engineering Dynamics. An Introduction to Modelling and Computer Simulation*, 2nd Edition, Wiley-VCH; Weinheim; Dunn, I.J., Heinzle, E., Ingham, J., Prenosil, J.E. (2003): *Biological Reaction Engineering. Dynamic Modelling Fundamentals with Simulation Exercises*. Wiley-VCH; Weinheim]. These books stimulated the organization of this book combining 50% basic theory with 50% case studies supplied as executable computer programs on an attached CD. Dr Arno Biwer studied biogeography at the Saarland University, where he made his PhD in the field of modeling and assessment of biotechnological processes. After a postdoctoral stay at MIT with Prof. C.L. Cooney, he moved back to the Saarland University to put together the book presented here.

The authors hope that they can contribute to the establishment of sustainable bioprocesses, which have a great potential to serve human needs and at the same time help to efficiently use renewable resources and to prevent pollution of our limited natural environment. The authors would be very grateful for any comments on the book. Please, use the corresponding web site <http://www.uni-saarland.de/dsbp>.

Acknowledgments

We greatly appreciate the financial support from the Deutsche Bundesstiftung Umwelt (DBU). This substantial support allowed Dr Biwer to fully dedicate his energy to this project for half a year. We are especially grateful to Prof. Stephanie Heiden from DBU, who was fascinated by this project from the very beginning and whose support was essential to complete this book. We are particularly grateful to all authors who contributed with most valuable case studies. We think that these case studies contain an invaluable wealth of information and support for students and experts setting up relevant process models. We thank Dr Demetri Petrides from Intelligen, Inc. who contributed a running version of SuperPro Designer™, a necessary platform to permit running the book's process models. We are very grateful to Dr Irving Dunn from ETH Zurich for reading the manuscript and making many very useful suggestions for improvement. We thank Dr Urs Saner from Roche for useful advice concerning aspects of economic assessment. We thank Erik Geibel who did a great job putting all figures in a perfect shape. We also appreciate the support from John Wiley & Sons, Ltd., particularly Lyn Roberts who helped initiate this project and Lynette James who accompanied and supported our work in the second phase.

List of Contributors

Jochen Buechs
Biochemical Engineering
RWTH Aachen University
Worringer Weg 1
52056 Aachen, Germany

Sindélia S. Freitas
Centre for Biological and Chemical Engineering
Instituto Superior Técnico
Av. Rovisco Pais
1049-001 Lisbon, Portugal

Justus von Geibler
Wuppertal Institute for Climate, Environment, Energy
Research Group Sustainable Production and Consumption
Döppersberg 19
42103 Wuppertal, Germany

M. Abdul Kholiq
Biochemical Engineering
Saarland University
P.O. Box 15 11 50
66041 Saarbrücken, Germany

Arnd Knoll
Biochemical Engineering
RWTH Aachen University
Worringer Weg 1
52056 Aachen, Germany

Christa Liedtke
Wuppertal Institute for Climate, Environment, Energy
Research Group Sustainable Production and Consumption
Döppersberg 19
42103 Wuppertal, Germany

Karen McDonald
Department of Chemical Engineering and Materials Science
One Shields Ave
University of California
Davis, CA 95616, USA

Rolf Metz
An der Bahn 11
76351 Lickenheim, Germany

Demetri Petrides
Intelligen, Inc.
2326 Morse Avenue
Scotch Plains, NJ 07076, USA

Duarte M.F. Prazeres
Centre for Biological and Chemical Engineering
Instituto Superior Técnico
Av. Rovisco Pais
1049-001 Lisbon, Portugal

José A.L. Santos
Centre for Biological and Chemical Engineering
Instituto Superior Técnico
Av. Rovisco Pais
1049-001 Lisbon, Portugal

Winfried Storhas
Biochemical Engineering
Mannheim University of Applied Sciences MUAS
Windeckstraße 110
D-68163 Mannheim, Germany

Holger Wallbaum
Wuppertal Institute for Climate, Environment, Energy
Research Group Sustainable Production and Consumption
Döppersberg 19
42103 Wuppertal, Germany

Elizabeth Zapalac
Department of Chemical Engineering and Materials Science
One Shields Ave
University of California
Davis, CA 95616

Part I

Theoretical Introduction

1

Introduction

1.1 Bioprocesses

1.1.1 History of Biotechnology and Today's Situation

Biotechnological processes have been essential for human survival and for satisfying various needs throughout human culture. Table 1.1 gives a short overview of the history of biotechnology. Early biotechnological processes that use microorganisms to produce a certain product have been used for several thousand years. The Egyptians brewed beer and baked bread in the 4th millennium BC. A basic purification step, the distillation of ethanol, was applied in the 2nd millennium BC in China. Modern biotechnology was started in the 19th century when general knowledge about biological systems, their components, and interactions between them grew [1.1]. In the first half of the 20th century the first large-scale fermentation processes, namely citric acid and penicillin, were realized. The progress of recombinant gene technology then led to a substantial increase in the number of bioprocesses and their production volume starting with insulin, the first product manufactured with recombinant technology, in the early 1980s.

While the first bioprocesses exclusively used fungi, bacteria and yeasts, the industrial production was later extended with the application of enzymes and mammalian cells. Other biocatalysts like plant and insect cells, and transgenic plants and animals were added to the available platform of technologies but are much less used in production so far. In parallel, fermentation and downstream technologies were further developed and the engineering knowledge about designing bioprocesses grew significantly.

Today, the bioindustries have reached a critical size and are additionally based on a broad understanding of genomics, proteomics, bioinformatics, genetic transformation, and molecular breeding. Table 1.2 shows the industries where bioprocesses are applied today. These different industries are reflected in the case studies in the second part of the book. The present worldwide sales of bioprocess products are reported to range between 13 and 60 billion dollars, depending on the source [1.2–1.4]. The share of the different product

Table 1.1 Milestones in the history of biotechnology (data taken largely from [1.2] and [1.5])

Time	Event
4th/3rd mill. BC	Baking, brewing (Egypt)
2nd mill. BC	Ethanol distillation (China)
17th century	Invention of microscope (A. von Leeuwenhoek, Netherlands)
18th century	First vaccination in Europe (cowpox) (E. Jenner, UK). Heat sterilization of food and organic material (Spallanzani, Italy)
1860–1890	Most amino acids isolated, first tyrosine (J. von Liebig, Germany)
1890s	<i>In vivo</i> synthesis and extraction of hormones from animal tissue
1921	Insulin isolated from pig pancreas (Toronto, Canada)
1920s	Mutation of microorganisms by X-rays and chemicals (e.g. H.J. Mueller, USA)
1923	Commercial production of citric acid (Pfizer, USA)
1940s	Production of penicillin by fermentation (USA)
1950s	Design and scale-up of large aerated fermenters. Elucidation of principles of sterile air filtration
1953	Discovery of the double helix of DNA (J. Watson and F. Crick, USA)
1972	Restriction enzymes (W. Arber, Switzerland)
1973	First recombinant DNA organism (S. Cohen and H. Boyer, USA)
1975	Monoclonal antibodies (G.J.F. Köhler and C. Milstein, UK/Germany)
1976	Genentech first specialist biotech company
1980s	Polymerase chain reaction (PCR). Large-scale protein purification from recombinant microorganisms
1982/1983	First genetically engineered product: human insulin (Eli Lilly/Genentech)
1982	First rDNA vaccine approved in Europe
1986	Release of genetically engineered plant
1995	First bacterial genome sequenced (<i>Haemophilus influenzae</i>)
1998	Isolation of human embryonic stem cells
2000/2001	Human genome sequenced

groups on these sales is shown in Table 1.3, where antibiotics and therapeutic proteins dominate due to their relatively high prices.

In 2000, there were 1270 bioscience companies in the U.S. and 1180 in the EU [1.5]. The six largest of them had revenues of \$8 billion and invested 20–37% of their revenues in research and development (R&D). The average investment spending for the pharmaceutical industries is 9–18%. The overall R&D spending in biotechnology was \$37 billion in 2000, with an expected growth rate of 30% per year [1.5].

The share of bioproducts differs from industry to industry. Some products are provided almost exclusively by bioprocesses, e.g. amino acids like lysine and glutamate, carboxylic acids, e.g. citric and lactic acid, and vitamins, e.g. vitamin B2 and vitamin C. One focus of bioprocesses is the pharmaceutical industry. Since the introduction of the centralized European drug-approval system in 1995, recombinant proteins count for 36% of all new drug approvals [1.6]. More than 100 new drugs and vaccines produced by bioprocesses have been brought to market since the mid 1970s and more than 400 are in clinical trials—the highest number ever [1.2, 1.5]. The average process development from laboratory to final

Table 1.2 Process industries versus process types. MO = microorganisms (bacteria, yeasts, fungi)

Industry	Scale	Downstream complexity	Biocatalyst	Products	Biotech market share
Basic chemicals	very large	low	MO/enzymes	organic small molecules	very low
Fine chemicals	medium	medium	MO/enzymes	organic small molecules	low
Detergents	large	low	MO	enzymes	medium
Health care/cosmetics	small–medium	medium–high	MO/enzymes/ mammalian cells	proteins and small molecules	medium
Pharma					
conventional biopharma	medium small	medium–high high	MO mammalian cells, MO	organic small molecules proteins	low– medium high
Food/feed	very large	medium	MO/enzymes	proteins and others	medium
Metal mining	very large	low	MO	metals/metal compounds	very low
Waste treatment	very large	low	MO	Purified water, air, and soil	high

Table 1.3 Market volume of bioproduct groups. Estimated overall sales were \$60 billion in 2000 (= 100%) (Data from [1.4])

Bioproduct group	Share of bioproduct sales (%)	Typical products
Antibiotics	42	penicillins, cephalosporins
Therapeutic proteins	25	interferon, insulin, antibodies
Other pharma- and animal health products	17	steroids, alkaloids
Amino acids	8	lysine, glutamate
Enzymes	3	proteases, cellulases, amylases
Organic acids	3	lactic acid, citric acid
Vitamins	1	B2, B12, biotin
Polysaccharides	1	xanthan, dextran

approval takes 10–15 years and costs \$300–800 million [1.5]. A short but comprehensive overview of present biotechnological production is provided in the book of R. Schmid [1.7].

1.1.2 Future Perspectives

The last decade brought an enormous stimulation from biological sciences combined with informatics, e.g. the genome sequences of man, plants, and microorganisms or the isolation of human stem cells. However, this knowledge waits to be transformed to technology and market products. The knowledge of molecular breeding, stem cell technology and pharmagenomics might lead to strongly personalized therapies and therapeutics.

It can be expected that biocatalysts such as insect and plant cells and transgenic plants and animals sooner or later will reach a much broader applicability, although this might not happen in the next decade. The increased use of extremophiles and their enzymes and biocatalysis in non-aqueous solution will broaden the technology platform for bioprocesses. Apart from the recombinant technology, the naturally occurring organisms also provide a huge reservoir of new products, e.g. the almost endless variety of plants, insects, and microorganisms in the tropical rain forests.

The share of bioprocesses in the different industries will rise substantially during the next decades. Additionally, bioprocesses will be used in industries where they are not used today or where only lab-scale processes are developed, e.g. the production of new materials with new properties that mimic natural materials. It is expected that the combination of biotechnology, nanotechnology, and information technology will lead to a substantial rate of progress and expansion [1.2]. The use of information technology has already led to improvements in the screening and development of new drugs and in the understanding of biological systems (bioinformatics). It might also lead to bio-chips for computers that replace silicon-based chips.

In the chemical industry it is expected that the sales from bioprocesses will rise to \$310 billion in 2010 and will then account for more than 20% of the overall sales of that industry [1.3]. Here, an increase is mainly expected for fine chemicals, especially chiral products. Compared with the chemical industry the bioindustries are still immature and production costs are relatively high. Therefore, not only do the strains and fermentations